# DESCRIPTION

- disclose government funding

## TECHNICAL FIELD OF THE INVENTION

- define technical field

## BACKGROUND OF THE INVENTION

- discuss tumor vasculature

## SUMMARY OF THE INVENTION

- outline method for delivery
- describe kit and composition

## DETAILED DESCRIPTION OF THE INVENTION

- introduce vascular-active permeability entities
- describe delivery of therapeutic or imaging agents
- define nanoparticles and their composition
- describe antibodies as therapeutic or imaging agents
- list examples of therapeutic agents
- list examples of imaging agents
- describe vascular-active permeability agents
- discuss limitations of chemotherapeutic agents
- introduce Enhanced EPR (E2PR) approach
- describe results of E2PR in GBM model
- discuss versatility of E2PR approach
- provide overview of invention

### Example 1

- describe cell lines used
- list reagents used
- describe animal models used
- describe liposomase antibody preparation
- describe radioiodination of antibodies
- describe preparation of liposomes
- describe radioiodination of Bolton-Hunter reagent
- describe biodistribution assay and SPECT-CT imaging

### Example 2

- motivate bacterial infection for tumor treatment

### Example 3

- describe bacterial infection enhancing antibody accumulation
- describe pro-inflammatory cytokine enhancing antibody accumulation
- describe effect of bacterial infection and cytokine on tumor-selective accumulation
- describe particle size dependence of enhanced EPR

### Example 4

- describe synergistic effect of TNF-Î± and macromolecular drug formulations
- describe therapeutic potential of E2PR in tumor treatment

